Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment

Not Applicable

Not yet recruiting

• Conditions: Diabetes
• Interventions: Drug: GZR4

• Registration Number: NCT07193147
• Lead Sponsor: Gan & Lee Pharmaceuticals.

Brief Summary

This is a multicenter, single-dose, open-label, parallel Phase 1 clinical study to evaluate the PK profile, safety, and tolerability of GZR4 Injection in subjects with mild, moderate, and severe hepatic impairment.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-09
• Study First Submitted: 2025-09-18
• Study First Submitted QC: 2025-09-18
• Last Update Submitted: 2025-09-18
• Study First Posted: 2025-09-25
• Last Update Posted: 2025-09-25
• Study Start: 2025-10-13
• Primary Completion: 2026-07-14
• Study Completion: 2026-11-04

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Subjects must meet all of the following inclusion criteria to be included in the study.

  1. Subjects must fully understand the study contents, study procedures and possible risks and voluntarily sign the informed consent form;
  2. Male or female subjects aged ≥ 18 years and ≤ 75 years;
  3. Subjects should have no plans for fertility, sperm, or egg donation during the study and for 8 weeks postdose. They should be willing to use effective contraceptive measures during the study and for 8 weeks postdose, be surgically sterilized, or be female subjects who have reached menopause.
  4. Only for Subjects with Hepatic Impairment: Subjects with chronic hepatic impairment caused by viral hepatitis, alcoholic liver disease, autoimmune hepatitis, or other reasons;
  5. Only for Subjects with Hepatic Impairment: Subjects with a prior diagnosis of hepatic cirrhosis confirmed through liver biopsy or other medical imaging techniques;
  6. Only for Subjects with Hepatic Impairment: Subjects who have not received albumin within 14 days and are classified as Class A, B, or C according to the Child-Pugh score, with hepatic impairment resulting from prior primary liver disorders;
  7. Only for Subjects with Hepatic Impairment: Subjects with normal or abnormal and not clinically significant vital signs, physical examination, laboratory tests (hematology, blood chemistry, coagulation function and urinalysis), 12-lead ECG, chest X-ray and B-ultrasonography.

Exclusion Criteria

• Subjects who meet any of the following criteria should not be enrolled in this study.

  1. Subjects with an allergic constitution, including a history of severe drug allergy or drug allergic reactions, who are known to be allergic to the investigational drug or its excipients (glycerol, phenol, m-cresol, zinc acetate dihydrate, sodium chloride, and citric acid monohydrate);
  2. Subjects with decompensated cardiac failure (NYHA Class III or IV) or those diagnosed with or highly suspected of having unstable angina pectoris or acute myocardial infarction, as well as those with malignant arrhythmias (such as ventricular fibrillation and sustained ventricular tachycardia) within 3 months before screening; subjects with a history of heart valve replacement surgery, coronary artery bypass grafting, or other invasive cardiovascular procedures, including percutaneous coronary intervention, as well as those who have experienced ischemic or hemorrhagic strokes (excluding lacunar infarctions) or transient ischemic attacks within 6 months before screening;
  3. Subjects with any clinically symptomatic bacterial, viral, parasitic, or fungal infection requiring systemic anti-infective therapy at screening (excluding hepatitis B and C in the hepatic impairment group), those with a history of severe active infection within 1 month before screening, or those who developed any acute infection requiring systemic anti-infective therapy within 2 weeks predose;
  4. Subjects with a history of drug abuse or drug addiction within 1 year before screening. Additionally, subjects with a positive urine drug abuse screening result predose (that cannot be attributed to concomitant medication) or a positive alcohol screening result;
  5. Subjects who are heavy smokers or alcohol consumers within 6 months before screening (consuming ≥ 14 units of alcohol per week: 1 unit ≈ 360 mL of beer, 45 mL of spirits, or 150 mL of wine; smoking ≥ 5 cigarettes per day), or those unable to abstain from smoking and alcohol for 48 h predose and during the study;
  6. Subjects who ingest grapefruit juice, food or beverage rich in methylxanthine (such as coffee, tea, cola, chocolate and functional drinks) within 7 days prior to dosing, or have strenuous exercise and other factors affecting drug absorption, distribution, metabolism and excretion, and cannot withdraw during the study;
  7. Pregnant or lactating women, women of child-bearing potential (WOCBP) with positive pregnancy test results at screening, or female subjects who have engaged in unprotected sexual intercourse within 2 weeks before screening;
  8. Subjects who are unwilling or unable to comply with the study procedures specified in the protocol, or who are deemed unsuitable for participating in this clinical study by any investigator.
  9. Subjects with hepatic impairment ：Subjects with a history of chronic or serious diseases in the circulatory system, digestive system, urinary system, immune system, blood system, endocrine and metabolic system, or mental and nervous system, or those who have the above conditions at screening that may interfere with the study results.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
GZR4 injection	GZR4	-

Primary Outcome Measures

Name	Time	Method
Cmax	through study completion, an average of 29 days	Maximum plasma concentration
AUC0-last	through study completion, an average of 29 days	Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose.

Secondary Outcome Measures

Name	Time	Method
AUC0-168h	Through study completion, an average of 29 days	Area under the plasma concentration-time curve from time zero to 168 hours
Tmax	Through study completion, an average of 29 days	Time of Maximum Drug ConcentrationTime to Maximum aentration
AUC0-inf	through study completion, an average of 29 days	Area under the plasma concentration-time curve at 0 h to infinity after a single dose.
TEAE	through study completion, an average of 29 days	Treatment Emergent Adverse Event

Trial Locations

Locations (1)

Gan & Lee Pharmaceuticals Shandong Co., Ltd.; 🇨🇳 Linyi, Shandong, China